Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $365

Author: Benzinga Newsdesk | April 03, 2024 10:23am
Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price target from $400 to $365.

Posted In: BIO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist